Oral care compositions

By using acidic polymers, nonionic polymers and polyamines in dental care products, the incompatibility problem caused by the interaction between cationic antibacterial agents and anionic polymers is solved, and antibacterial agents are improved The delivery efficiency and dental care effect inhibit tooth coloration and biofilm formation.

CN115350117BActive Publication Date: 2024-11-26COLGATE PALMOLIVE CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210820035.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2016-11-08
Filing Date
2017-11-07
Publication Date
2024-11-26
Estimated Expiration
2037-11-07

AI Technical Summary

Technical Problem

In the prior art, cationic antibacterial agents interact with anionic polymers in high water formulations, resulting in incompatibility, inhibiting the delivery of antibacterial agents and polymers, and teeth coloring and biofilm formation are difficult to effectively inhibit.

Method used

An unusual biphasic system is formed using an aqueous solution containing acid polymers, nonionic polymers and polyamines. The polyamine interacts with the acid polymer to form one aqueous phase, and the nonionic polymer separates it to form another water. The phase separation degree and proportion are adjusted to mix the phase, increasing the delivery efficiency of antibacterial agent and the local active concentration.

Benefits of technology

The stable combination of cationic antibacterial agent and anionic polymer is achieved, the delivery efficiency and local active substance concentration of the antibacterial agent are improved, the coloring of teeth and the formation of biofilms are inhibited, and the aesthetic effect and functional benefits are provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003743888850000041
    Figure BDA0003743888850000041
  • Figure BDA0003743888850000061
    Figure BDA0003743888850000061
  • Figure BDA0003743888850000062
    Figure BDA0003743888850000062
Patent Text Reader

Abstract

Oral care compositions. The present application particularly relates to novel dual-phase compositions for combining and delivering poorly compatible ingredients, for example, to deliver effective levels of cationic antimicrobial agents in combination with polymers that protect against erosion and staining. The present application particularly provides novel aqueous dual-phase compositions comprising two different aqueous phases that can be used to combine and deliver poorly compatible ingredients, for example, to deliver effective levels of cationic antimicrobial agents in combination with anionic polymers that protect against erosion and staining by adding a stabilizing amount of a polyamine such as lysine, and methods of making and using the compositions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese patent application with application number 201780069124.7 and invention name “Oral Care Composition”. The parent application is the PCT international patent application PCT / US2017 / 060268 filed on November 7, 2017, which entered the Chinese national phase. Technical Field

[0002] In particular, the present application relates to novel dual phase compositions for combining and delivering poorly compatible ingredients, for example, to deliver effective levels of cationic antimicrobial agents in combination with erosion and staining protection polymers. Background Art

[0003] Biofilms are formed when bacteria adhere to surfaces in some form of aqueous environments and begin to secrete a sticky, jelly-like substance that can adhere to all kinds of materials - metals, plastics, soil particles, medical implants, biological tissues. Dental plaque is a biofilm that adheres to teeth and other oral surfaces, especially at the gingival margin, and is associated with the occurrence of gingivitis, periodontitis, caries and other forms of periodontal disease. Dental plaque is cohesive and highly resistant to removal from teeth and / or oral surfaces. Bacteria associated with dental plaque convert sugars into glucans, which are insoluble polysaccharides that provide plaque with its cohesiveness. Anaerobic bacteria in plaque metabolize sugars to produce acids that dissolve tooth minerals, thereby destroying tooth enamel and eventually forming caries. Saliva can buffer the acid produced by bacteria and promote the remineralization of tooth enamel, but extensive plaque can block saliva from contacting tooth enamel. The redeposition of minerals in biofilms forms a hard deposit called calculus (or tartar) on teeth, which becomes a local irritant to the gums, causing gingivitis.

[0004] Various antimicrobial agents can retard the growth of bacteria and thus reduce the formation of biofilm on oral surfaces. In many cases, these antimicrobial agents are cationic, for example, quaternary ammonium surfactants such as cetylpyridinium chloride (CPC), biguanides such as chlorhexidine, metal cations such as zinc or stannous ions, and guanidines such as arginine.

[0005] Everyday activities such as smoking or other oral use of tobacco products, and eating, chewing or drinking certain foods and beverages (particularly coffee, tea, cola drinks and red wine) can cause unwanted staining of the tooth surface. Staining can also result from microbial activity, including that associated with dental plaque. Chromogens, or color-causing substances, in these materials become part of the salivary film layer and can penetrate the tooth enamel layer. Even with regular brushing and flossing, chromogen accumulation over the years can cause noticeable tooth discoloration.

[0006] Teeth contain an inner dentin layer and an outer hard enamel layer, which is a protective layer of the teeth. The enamel layer of teeth is naturally opaque and white or slightly off-white. The enamel layer is composed of hydroxyapatite mineral crystals that create a somewhat porous surface. These hydroxyapatite crystals form fine hexagonal rods or prisms to form the enamel surface. Therefore, the surface of the enamel has tiny spaces or pores between the prisms. Without limiting the mechanism, function or utility of the present disclosure, it is believed that this porosity of the enamel is the reason why discoloring substances penetrate the enamel and discolor the teeth.

[0007] Since tooth-staining compounds are generally anionic materials, cationic antimicrobials may cause or enhance staining by promoting the deposition of chromogens or by forming salts with minerals.

[0008] One way to reduce staining and erosion and reduce biofilm formation is to use anionic polymers, which help coat and protect tooth enamel, thereby preventing bacterial attachment and repelling chromogens. However, these polymers can interact with cationic antimicrobials, leading to formulation incompatibility, especially in high-water formulations such as mouthwashes, and inhibiting the delivery of antimicrobials and / or polymers. Oral care products containing such polymers are disclosed, for example, in WO 2015094336 A1, which is incorporated herein by reference.

[0009] Therefore, there is a need for new compositions and methods that minimize interactions between incompatible ingredients in formulations, enhance delivery of active agents, and inhibit coloration and / or biofilm formation. Summary of the invention

[0010] It was unexpectedly discovered that formulations comprising aqueous solutions of:

[0011] a) acidic polymers, e.g. having an isoelectric point of less than pH 5;

[0012] b) nonionic polymers, such as poly(oxyalkylenes);

[0013] c) a polyamine compound, for example, having an isoelectric point of at least pH 8.5, for example pH 9-10, such as lysine in free or salt form; and

[0014] d) water,

[0015] The formulation can form an unusual two-phase system, wherein the polyamine compound interacts with the acidic polymer to form one aqueous phase, while the nonionic polymer separates to form a second aqueous phase, both phases being therefore aqueous, but having different compositions and densities. If the formulation is shaken to mix the phases, the phases will separate again when the material is left to stand. In certain embodiments, a cationic agent, such as a cationic antimicrobial agent, may be included in the formulation, which will concentrate in the lower phase. The two-phase feature provides an interesting aesthetic effect, since the addition of dyes makes the two phases visually distinct, and the formulation also provides functional benefits by enabling otherwise incompatible agents to be combined. When the phases are mixed, such as by shaking before use, the anionic polymer and any cationic agent are delivered as droplets having a relatively high concentration of the anionic polymer and, if present, the cationic active substance, thereby providing improved delivery and a high local active concentration at the delivery site compared to a homogeneous solution. These formulations differ from conventional two-phase formulations in that both phases are aqueous, rather than one phase being hydrophobic and the other being hydrophilic. They also differ from structured compositions such as gels in that they will separate into phases of different densities, e.g., an upper phase and a lower phase, which can be easily mixed by shaking and then re-separated upon standing within a short period of time.

[0016] The degree of separation, the relative proportions of the two layers, and the time required to form the two discrete layers can be adjusted by varying the polymer and polyamine content. Dual phases with different top and bottom layers, each containing different materials and potentially different actives, or at least different concentrations of actives, can be used in a variety of applications, such as for oral care, such as in mouthwashes or other rinse products.

[0017] In certain embodiments, the invention provides compositions forming biphasic aqueous solutions that use only water-soluble materials instead of oil. In other embodiments, the aqueous biphasic composition is further combined with an oil phase to obtain a three-phase system, wherein two phases are aqueous and the third phase is oil-based. In one example, the top layer is primarily composed of mineral oil, the middle layer is primarily composed of water and nonionic polymers, and the bottom layer is primarily composed of anionic polymers and polyamines. These three phases will mix when stirred, and then the layers will separate when standing. This allows the delivery of other combinations of otherwise insoluble or incompatible active compounds.

[0018] For example, cetylpyridinium chloride (CPC) can be used as an antimicrobial agent, while anionic polymers can be used to help remove and inhibit staining. These ingredients are generally incompatible because they interact, resulting in reduced effectiveness of the two ingredients or even precipitation of the two components. The addition of lysine will provide the required stability and competition between the acid functional groups of the polymer, the acid and amine functional groups of lysine and CPC - the result is to free CPC and make it more available for interaction with bacteria. In certain embodiments, the addition of glutamic acid also improves CPC availability by additional competitive pathways via carboxylates on glutamic acid. In the absence of lysine (and optionally glutamic acid), formulations with CPC and anionic polymers may hardly have better effectiveness than materials or medium controls that do not contain CPC.

[0019] Similarly, chlorhexidine will usually be complexed with anionic polymers regardless of the procedure, given their high charge density and entropy-driven precipitation reactions. However, we have found that chlorhexidine and anionic polymers can be formulated in a way to prevent precipitation (or to redissolve the precipitate) by introducing lysine (Lys), polyethylene glycol (PEG), and low levels of anionic surfactants such as sodium lauryl sulfate (SLS). Additional nonionic surfactants such as poloxamers can be used to supplement the SLS portion.

[0020] In one embodiment, the present disclosure therefore provides a composition comprising an aqueous solution of:

[0021] (i) an acidic polymer, e.g. a polymer having an isoelectric point below pH 5, e.g. selected from one or more of the following: (a) a synthetic anionic linear polycarboxylate, such as a 1:4 to 4:1 copolymer of maleic anhydride or acid with another polymerizable ethylenically unsaturated monomer, e.g. a copolymer of methyl vinyl ether / maleic anhydride in which some or all of the anhydride moieties are hydrolyzed to provide free carboxyl groups, and (b) a phosphate / acrylate copolymer, e.g. a polymer composed of an acrylate monomer and a phosphate-bearing monomer, e.g. the copolymerization product of a mixture of acrylic acid, methacrylic acid and 2-hydroxyethyl methacrylate phosphate of Formula 1:

[0022]

[0023] wherein n is 0, 1 or 2; and mixtures thereof; for example wherein the orally acceptable acidic polymer has a molecular weight of at least 7500D, for example 10 kD to 1500 kD;

[0024] (ii) a non-ionic polymer, e.g. selected from one or more poly(oxyalkylene) polymers, e.g. selected from polyethylene glycol, polypropylene glycol, poloxamer and mixtures thereof; e.g., wherein the non-ionic polymer has a molecular weight of at least 3000D, e.g., from 6 kD to 250 kD;

[0025] (iii) optionally an effective amount of a cationic active agent in free or orally acceptable salt form, for example one or more selected from the group consisting of a quaternary ammonium surfactant (e.g. a pyridinium salt such as cetylpyridinium chloride (CPC)), a biguanide such as chlorhexidine digluconate, a cationic amino acid such as arginine, in free or salt form, a metal cation such as zinc, calcium or stannous ions, or a combination thereof;

[0026] (iv) a stabilizing amount of a polyamine, e.g., having an isoelectric point above pH 8.5, e.g., lysine, which may be added, e.g., in free or salt form; and

[0027] (v) Water.

[0028] The solution comprises two different aqueous phases having different compositions and densities.

[0029] The present disclosure also provides methods of using such compositions, for example, to inhibit dental erosion, staining, and / or biofilm formation.

[0030] Other areas of applicability of the present invention will become apparent from the detailed description provided below.It should be understood that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are intended for illustrative purposes only and are not intended to limit the scope of the present invention. DETAILED DESCRIPTION

[0031] The following description of the preferred embodiment is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses.

[0032] Ranges used throughout the text are used as shorthand for describing each value within the range. Any value within the range can be selected as the range endpoint. In addition, all references cited herein are incorporated by reference in their entirety. If a definition in the present disclosure conflicts with a definition in the cited reference, the present disclosure shall prevail.

[0033] Unless otherwise specified, all percentages and amounts expressed here and elsewhere in the specification should be understood to refer to percentages by weight. The amounts given are based on the effective weight of the material.

[0034] As is common in the art, compositions described herein are sometimes described in terms of their ingredients, although the ingredients may dissociate, associate, or react in the formulation. For example, ions are often provided to the formulation in the form of salts that can dissolve and dissociate in aqueous solutions. It should be understood that the present invention encompasses both mixtures of the ingredients and the products obtained therefrom.

[0035] In a first embodiment, the present disclosure provides a composition (Composition 1) comprising an aqueous solution of:

[0036] Acidic polymers;

[0037] Nonionic polymers;

[0038] Optionally an effective amount of a cationic active agent;

[0039] a stabilizing amount of a polyamine compound; and

[0040] water;

[0041] The solution comprises two different aqueous phases having different compositions and densities.

[0042] For example, the present disclosure provides the following composition 1 embodiment:

[0043] 1.1 Composition 1, wherein the acidic polymer is in linear or branched form or a mixture thereof, has acidic functional groups to provide an isoelectric point of pH 5 or lower, and optionally also has uncharged spacers or side chains, for example, comprising a hydrophobic portion (such as methyl methacrylate monomer or an alkane chain) and / or an uncharged hydrophilic portion (such as a polyalkylene glycol).

[0044] 1.2 Composition 1 or 1.1, wherein the acidic polymer is selected from one or more of synthetic anionic linear polycarboxylates, phosphate / acrylate copolymers and combinations thereof.

[0045] 1.3 Composition 1 or 1.1, wherein the acidic polymer is selected from one or more of the following: (a) a 1:4 to 4:1 copolymer of maleic anhydride or acid and another polymerizable ethylenically unsaturated monomer, such as a copolymer of methyl vinyl ether / maleic anhydride, in which some or all of the anhydride moieties are hydrolyzed to provide free carboxyl groups, and (b) the copolymerization product of a mixture of acrylic acid, methacrylic acid and 2-hydroxyethyl methacrylate phosphate of Formula 1:

[0046]

[0047] wherein n is 0, 1 or 2; and mixtures thereof;

[0048] For example wherein the orally acceptable acidic polymer has a molecular weight of at least 7500D, such as 10 kD to 1500 kD.

[0049] 1.4 Any of the preceding compositions, wherein the acidic polymer comprises a phosphate / acrylate copolymer which is the copolymerization product of a mixture of acrylic acid, methacrylic acid, and 2-hydroxyethyl methacrylate phosphate of Formula 1:

[0050]

[0051] Where n is 0, 1, or 2.

[0052] 1.5 Any of the preceding compositions, wherein the acidic polymer comprises a phosphate / acrylate copolymer, wherein the phosphate / acrylate copolymer is a copolymerization product of a mixture of acrylic acid, methacrylic acid and 2-hydroxyethyl methacrylate phosphate of Formula 1, comprising 80-90%, such as about 85%, by mole percent of acrylic acid; 5-15%, such as about 11% by mole percent of methacrylic acid and 2-6%, such as about 4% by mole percent of hydroxyethyl methacrylate phosphate of Formula 1.

[0053] 1.6 Any of the preceding compositions, wherein the acidic polymer comprises a phosphate / acrylate copolymer, wherein the phosphate / acrylate copolymer has an average molecular weight of 10 to 40 kDa, such as 20 to 30 kDa.

[0054] 1.7 Any of the preceding compositions, wherein the acidic polymer comprises a phosphate / acrylate copolymer, wherein the phosphate / acrylate copolymer is a random copolymer having a weight average molecular weight of about 20,000 to 30,000 grams per mole, the random copolymer being a copolymerization product of a mixture of acrylic acid, methacrylic acid, and 2-hydroxyethyl methacrylate phosphate of Formula 1 in a molar ratio of about 85:11:4.

[0055] 1.8 Any of the foregoing compositions, wherein the acidic polymer comprises 0.1 to 10 wt % of a phosphate / acrylate copolymer, such as 0.2 to 9 wt % of a phosphate / acrylate copolymer, such as 0.3 to 8 wt % of a phosphate / acrylate copolymer, such as 0.4 to 7 wt % of a phosphate / acrylate copolymer, such as 0.5 to 6 wt % of a phosphate / acrylate copolymer, such as 0.5 to 5 wt % of a phosphate / acrylate copolymer, such as 0.5 to 4 wt % of a phosphate / acrylate copolymer, such as 0.5 to 3 wt % of phosphate / acrylate copolymer, such as 0.5 to 2 wt % of phosphate / acrylate copolymer, such as 1 to 10 wt % of phosphate / acrylate copolymer, such as 1 to 8 wt % of phosphate / acrylate copolymer, such as 1 to 6 wt % of phosphate / acrylate copolymer, such as 1 to 5 wt % of phosphate / acrylate copolymer, such as 1 to 4 wt % of phosphate / acrylate copolymer, such as 1 to 3 wt % of phosphate / acrylate copolymer, such as 1 to 2 wt % of phosphate / acrylate copolymer.

[0056] 1.9 Any of the preceding compositions, wherein the acidic polymer comprises 0.01 to 30 wt % of a synthetic anionic linear polycarboxylate, such as 0.1 to 30 wt % of a synthetic anionic linear polycarboxylate, such as 1 to 30 wt % of a synthetic anionic linear polycarboxylate, such as 5 to 30 wt % of a synthetic anionic linear polycarboxylate, such as 10 to 30 wt % of a synthetic anionic linear polycarboxylate, such as 10 to 20 wt % of a synthetic anionic linear polycarboxylate, such as 15 wt % of a synthetic anionic linear polycarboxylate, such as 17 wt % of a synthetic anionic linear polycarboxylate.

[0057] 1.10 Any of the preceding compositions wherein the acidic polymer comprises a copolymer of maleic anhydride and methyl vinyl ether.

[0058] 1.11 Any of the preceding compositions wherein the acidic polymer comprises a 1:4 to 4:1 copolymer of methyl vinyl ether / maleic anhydride (optionally fully or partially hydrolyzed after copolymerization to provide the corresponding acid).

[0059] 1.12 Any of the preceding compositions wherein the acidic polymer comprises a 1:4 to 4:1 copolymer of methyl vinyl ether / maleic anhydride (optionally fully or partially hydrolyzed after copolymerization to provide the corresponding acid) having a molecular weight (MW) of about 30,000 to about 1,000,000, e.g., about 300,000 to about 800,000.

[0060] 1.13 Any of the preceding compositions wherein the acidic polymer comprises a combination of a copolymer of maleic anhydride and methyl vinyl ether and a phosphate / acrylate copolymer.

[0061] 1.14 Any of the preceding compositions wherein the acidic polymer comprises a combination of (i) a copolymer of maleic anhydride and methyl vinyl ether and (ii) a phosphate / acrylate copolymer in a weight ratio of about 1:1.

[0062] 1.15 Any of the preceding compositions wherein the acidic polymer comprises 0.5% to 2% copolymer of maleic anhydride and methyl vinyl ether and 0.5% to 2% phosphate / acrylate copolymer.

[0063] 1.16 Any of the preceding compositions, wherein the acidic polymer comprises a combination of (i) and (ii), wherein (i) is a 1:4 to 4:1 copolymer of methyl vinyl ether / maleic anhydride (optionally fully or partially hydrolyzed after copolymerization to provide the corresponding acid) having a molecular weight (MW) of about 30,000 to about 1,000,000, such as about 300,000 to about 800,000; and (ii) is a phosphate / acrylate copolymer, wherein the phosphate / acrylate copolymer is a copolymerization product of a mixture of acrylic acid, methacrylic acid and 2-hydroxyethyl methacrylate phosphate of Formula 1, comprising 80-90%, such as about 85%, by mole percent of acrylic acid; 5-15%, such as about 11%, by mole percent of methacrylic acid and 2-6%, such as about 4%, by mole percent of hydroxyethyl methacrylate phosphate of Formula 1.

[0064] 1.17 Any of the preceding compositions wherein the acidic polymer is present in a total amount of 1% to 3%.

[0065] 1.18 Any of the preceding compositions wherein the acidic polymer comprises a phosphate / acrylate copolymer in an amount of 1 to 12%; eg, 2-4%.

[0066] 1.19 Any of the preceding compositions wherein the nonionic polymer is selected from one or more poly(oxyalkylene) polymers.

[0067] 1.20 Any of the preceding compositions wherein the nonionic polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, poloxamers, copolymers of polyethylene glycol and polypropylene glycol, and mixtures thereof.

[0068] 1.21 Any of the preceding compositions wherein the nonionic polymer has a molecular weight of at least 3000D, such as from 6 kD to 250 kD.

[0069] 1.22 Any of the preceding compositions wherein the nonionic polymer comprises polyethylene glycol of MW 5kDa-35kDa in an amount of 5% to 8%.

[0070] 1.23 Any of the preceding compositions wherein the nonionic polymer is 5-8% polyethylene glycol having a molecular weight of 5 kD to 10 kD.

[0071] 1.24 Any of the preceding compositions wherein the composition comprises a cationic active agent, such as a cationic antimicrobial agent.

[0072] 1.25 Any of the preceding compositions wherein the composition comprises a cationic active agent as an antimicrobial agent at an antimicrobially effective concentration.

[0073] 1.26 Any of the preceding compositions, wherein the composition comprises a cationic active agent, for example, selected from one or more of the following: a quaternary ammonium surfactant (e.g., cetylpyridinium chloride (CPC), benzalkonium chloride, cetyltrimethylammonium bromide or cetyltrimethylammonium chloride, didecyldimethylammonium chloride, benzethonium chloride), a biguanide (e.g., chlorhexidine digluconate), a cationic amino acid (e.g., arginine), a metal cation (e.g., zinc, calcium, or stannous ions), or a combination thereof.

[0074] 1.26.1. Any of the foregoing compositions, wherein the composition is an oral care product, such as a mouthwash, and comprises an effective amount of an orally acceptable antimicrobial cationic active agent selected from one or more of the following: a quaternary ammonium surfactant (such as cetylpyridinium chloride (CPC)), a biguanide (such as chlorhexidine digluconate), a cationic amino acid (such as arginine), a metal cation (such as zinc, calcium or stannous ion), or a combination thereof; or

[0075] 1.27 Any of the preceding compositions wherein the composition comprises a cationic active agent comprising a pyridine surfactant, such as cetylpyridinium chloride (CPC).

[0076] 1.28 Any of the preceding compositions wherein the composition comprises a cationic active agent comprising chlorhexidine.

[0077] 1.29 Any of the preceding compositions wherein the composition comprises a cationic active agent comprising arginine.

[0078] 1.30 Any of the preceding compositions wherein the composition comprises a cationic active agent comprising zinc ions.

[0079] 1.31 Any of the preceding compositions wherein the composition comprises a cationic active agent provided by an orally acceptable salt selected from zinc salts, stannous salts, pyridinium salts and biguanide salts.

[0080] 1.32 Any of the preceding compositions wherein the composition comprises a cationic active agent provided by a salt selected from cetylpyridinium chloride and chlorhexidine digluconate.

[0081] 1.33 Any of the preceding compositions wherein the composition comprises a cationic active agent provided by a zinc salt, a stannous salt, or a combination thereof.

[0082] 1.34 Any of the preceding compositions wherein the effective amount of a cationic active agent in free or salt form is present in an amount of 0.05 to 0.1%, such as about 0.075%, and comprises cetylpyridinium chloride.

[0083] 1.35 Any of the preceding compositions wherein the effective amount of a cationic active agent in free or salt form is present in an amount of 0.1 to 0.2%, such as about 0.12%, and comprises chlorhexidine digluconate.

[0084] 1.36 Any of the preceding compositions, which comprises an antimicrobial phenolic compound, for example selected from magnolia extract compounds (e.g., magnolol or honokiol), phenol, cresols (e.g., thymol), halogenated (e.g., chlorinated or brominated) phenols (e.g., hexachlorophenol, trichlorophenol, tribromophenol or pentachlorophenol); or an antimicrobial halogenated diphenyl compound, for example, triclosan or triclocarban.

[0085] 1.37 Any of the preceding compositions wherein the polyamine compound comprises lysine in free or salt form.

[0086] 1.38 Any of the preceding compositions wherein the stabilizing amount of the polyamine compound is an amount sufficient to substantially interfere with the interaction between the cationic active agent and the acidic polymer, such as an amount sufficient to inhibit the formation of a precipitate or reduce the efficacy of the cationic active agent.

[0087] 1.39 Any of the preceding compositions wherein the composition comprises 1%-5% lysine in free or salt form.

[0088] 1.40 Any of the preceding compositions, wherein the polyamine is lysine in free or salt form and the composition further comprises glutamic acid in free or salt form, wherein the combined amount of lysine and glutamic acid is 1 to 10%; for example, lysine and glutamic acid are combined in a weight ratio of lysine:glutamic acid of 3:1 to 5:1, wherein the weight % is calculated based on the weight of the free amino acids.

[0089] 1.41 Any preceding composition wherein the composition comprises lysine in the form of the hydrochloride salt.

[0090] 1.42 Any of the preceding compositions wherein the composition comprises 2%-4% lysine hydrochloride.

[0091] 1.43 Any of the preceding compositions further comprising glutamic acid in free or salt form,

[0092] 1.44 Any of the preceding compositions wherein the polyamine in free or orally acceptable salt form is lysine and the composition further comprises glutamic acid, the lysine and the glutamic acid each in free or orally acceptable salt form in a total amount of 1 to 10%.

[0093] 1.45 Any of the preceding compositions, wherein the polyamine in free or orally acceptable salt form is lysine and the composition further comprises glutamic acid, the lysine and the glutamic acid each being in free or orally acceptable salt form, and the weight ratio of lysine:glutamic acid is from 3:1 to 5:1, weight calculated on a free amino acid basis.

[0094] 1.46 Any of the preceding compositions wherein the composition comprises taurine, eg, 0.3-3% taurine.

[0095] 1.47 Any of the preceding compositions wherein the composition comprises greater than 50% water.

[0096] 1.48 Any of the preceding compositions wherein the composition comprises 70% to 95% water.

[0097] 1.49 Any of the preceding compositions, wherein the composition comprises one or more of the following: a thickener, a buffer, a humectant, a surfactant, an abrasive, a sweetener, a flavoring agent, a pigment, a dye, an anticaries agent, an antibacterial agent, a whitening agent, a desensitizing agent, a preservative, or a mixture thereof.

[0098] 1.50 Any of the preceding compositions wherein the composition contains a blueing agent, such as a blue dye or a blue pigment, such as to impart color to the composition and / or provide a whiter appearance to a yellow surface (eg, a tooth surface).

[0099] 1.51 Any of the preceding compositions wherein the composition comprises a phosphate buffer.

[0100] 1.52 Any of the preceding compositions wherein the composition comprises a buffer, wherein the buffer comprises sodium hydroxide.

[0101] 1.53 Any of the preceding compositions wherein the composition comprises a humectant.

[0102] 1.54 Any of the preceding compositions wherein the composition comprises a humectant, wherein the humectant is a mixture of glycerin, sorbitol, and propylene glycol.

[0103] 1.55 Any of the preceding compositions wherein the composition comprises an anionic surfactant.

[0104] 1.56 Any of the preceding compositions wherein the composition comprises an anionic surfactant, wherein the anionic surfactant is selected from sodium laureth sulfate and sodium lauryl sulfate.

[0105] 1.57 Any of the preceding compositions wherein the composition comprises an abrasive.

[0106] 1.58 Any of the preceding compositions wherein the composition comprises an abrasive, wherein the abrasive comprises silica.

[0107] 1.59 Any of the preceding compositions wherein the composition comprises a sweetener.

[0108] 1.60 Any of the preceding compositions wherein the composition comprises a sweetener, wherein the sweetener is sodium saccharin.

[0109] 1.61 Any of the preceding compositions wherein the composition comprises a flavoring agent.

[0110] 1.62 Any of the preceding compositions wherein the composition comprises a dye.

[0111] 1.63 Any of the preceding compositions wherein the composition comprises an anticaries agent.

[0112] 1.64 Any of the preceding compositions wherein the composition comprises a fluoride ion source.

[0113] 1.65 Any of the preceding compositions, wherein the composition comprises a fluoride ion source, wherein the fluoride ion source is stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, an amine fluoride (e.g., N'-octadecyltrimethylenediamine-N,N,N'-tris(2-ethanol)-dihydrofluoride), ammonium fluoride, titanium fluoride, hexafluorosulfate, or a mixture thereof.

[0114] 1.66 Any of the preceding compositions wherein the composition comprises a whitening agent.

[0115] 1.67 Any of the preceding compositions wherein the composition comprises a whitening agent, wherein the whitening agent is hydrogen peroxide.

[0116] 1.68 Any of the preceding compositions, wherein the composition comprises a desensitizing agent, a vitamin, a preservative, an enzyme, or a mixture thereof.

[0117] 1.69 Any of the preceding compositions, wherein each of the anionic polymer, the nonionic polymer, the polyamine, and the cationic active agent (if any) are individually orally acceptable, e.g., safe for administration to the human oral cavity at relevant concentrations.

[0118] 1.70 Any of the preceding compositions, wherein the composition is a mouthwash, toothpaste, tooth gel, tooth powder, non-abrasive gel, foam, oral spray, lozenge, oral tablet, dental appliance, or pet care product.

[0119] 1.71 Any of the preceding compositions, wherein the composition is a mouthwash, e.g., wherein all ingredients of the composition are orally acceptable, e.g., safe and palatable for administration to the human oral cavity at relevant concentrations.

[0120] 1.72 Any of the preceding compositions which is biphasic wherein one phase comprises at least 90% of an orally acceptable acidic polymer, an orally acceptable cationic active agent and lysine or polylysine and the other phase comprises at least 90% of an orally acceptable nonionic polymer.

[0121] 1.73 Any of the preceding compositions comprising less than 5%, such as less than 2%, of a hydrophobic component.

[0122] 1.74 Any of the preceding compositions which, except for flavoring agents, is substantially free of oil.

[0123] 1.75 Any of compositions 1-1.69 further comprising an oil phase, for example comprising mineral oil.

[0124] 1.76 Any of the preceding compositions having a pH between the isoelectric point of the acidic polymer and the isoelectric point of the polyamine compound.

[0125] 1.77 Any of the preceding compositions having a pH of 5.5 to 8.0.

[0126] 1.78 Any of the preceding compositions having a pH of 5.5 to 6.5.

[0127] 1.79 Any of the preceding compositions further comprising an anionic surfactant.

[0128] 1.80 Any of the preceding compositions further comprising sodium lauryl sulfate in an amount up to 1%.

[0129] 1.81 Any of the preceding compositions further comprising sodium lauryl sulfate, e.g., 0.1-1.5%.

[0130] 1.82 Any of the preceding compositions which is a mouthwash comprising 1-2%, e.g., about 2.5%, of a phosphate / acrylate copolymer having a molecular weight of 20 to 30 kDa; 0.05-0.1%, e.g., about 0.075%, of cetylpyridinium chloride; 0.5-2%, e.g., about 1% glutamic acid; 3-5%, e.g., about 4% lysine; 5-7%, e.g., about 6% of a polyethylene glycol having a molecular weight of 8-12 kDa, e.g., about 10 kDa; and 80-90% water.

[0131] 1.83 Any of the preceding compositions, wherein the composition has any one or more or all of the following features:

[0132] a) the acidic polymer comprises a combination of a phosphate ester / acrylate copolymer and a methyl vinyl ether / maleic anhydride copolymer, the total amount being 1% to 5%, for example about 2%;

[0133] b) the nonionic polymer comprises a combination of (i) polyethylene glycol having an average molecular weight of 5 kDa to 35 kDa, such as PEG8k or PEG 35k, and (ii) poloxamer 407, in a total amount of 3 to 10%, such as 2-5% polyethylene glycol and 0.5-2% poloxamer;

[0134] c) the cationic active agent is present in an effective amount, in free or orally acceptable salt form, and comprises cetylpyridinium chloride in an amount of 0.05 to 0.1%, such as about 0.075%;

[0135] d) the polyamine in free or salt form is lysine; and

[0136] e) the water is present in an amount of 70-95%;

[0137] The composition is a mouthwash and further comprises a humectant, such as 1%-2.5% (e.g., about 1%) propylene glycol, a flavoring agent, a sweetener, a preservative (e.g., 0.04%-0.06% potassium sorbate), and a dye (e.g., blue dye #1).

[0138] wherein all ingredients are orally acceptable, e.g., safe and palatable at concentrations relevant for use in mouthwashes, and

[0139] All amounts herein are by weight of the total composition.

[0140] 1.84 Any of the preceding compositions wherein upon standing after shaking to mix the phases, the phases separate within 30 minutes, e.g. 15 minutes, at room temperature.

[0141] 1.85 Any of the foregoing compositions, except those specifically designated as oral care compositions.

[0142] 1.86 Any of the foregoing compositions, wherein

[0143] a) the acidic polymer is selected from phosphate / acrylate copolymers, methyl vinyl ether / maleic anhydride copolymers and mixtures thereof, with a total amount of 1 to 12%;

[0144] b) the nonionic polymer is selected from polyethylene glycol with a molecular weight of 5 kD to 35 kD and poloxamer 407 in an amount of 0 to 2% and mixtures thereof, with a total amount of 3 to 10%;

[0145] c) the effective amount of an orally acceptable cationic active agent in free or orally acceptable salt form is present in an amount of 0.05 to 0.1% and comprises cetylpyridinium chloride;

[0146] d) the polyamine compound comprises lysine in the form of free or orally acceptable salts in a total amount of 1 to 10%; and

[0147] e) the water is present in an amount of 35-95%;

[0148] wherein the composition optionally further comprises an anionic surfactant and / or glutamic acid; and

[0149] All amounts herein are by weight of the total composition.

[0150] Also claimed is the use of a polyamine, such as lysine, in free or orally acceptable salt form, such as according to any of Compositions 1 et seq., e.g. comprising an acidic polymer, a nonionic polymer and optionally an effective amount of a cationic active agent, in free or orally acceptable salt form; such as for use in any of the aforementioned Compositions 1 et seq.

[0151] As used herein, "oral care composition" refers to a composition whose intended use may include oral care, oral hygiene or oral appearance or whose intended method of use may include administration to the oral cavity. The term "oral care composition" therefore explicitly excludes compositions that are highly toxic, poor in taste, or are not suitable for administration to the oral cavity for other reasons. In some embodiments, the oral care composition is not intended to be swallowed, but is retained in the oral cavity for a sufficient time to achieve the intended utility. Oral care compositions as disclosed herein can be used in non-human mammals such as pets (e.g., dogs and cats) and for use by humans. In some embodiments, oral care compositions as disclosed herein are used by humans. Oral care compositions include, for example, dentifrices and mouthwashes. In some embodiments, the disclosure provides mouthwash formulations.

[0152] As used herein, "orally acceptable" refers to materials that are safe and palatable at relevant concentrations for use in oral care formulations such as mouthwashes or dentifrices.

[0153] As used herein, "orally acceptable carrier" refers to any carrier that can be used to formulate the oral care compositions disclosed herein. When retained in the mouth for a time sufficient to allow effective contact with the tooth surface as required herein without swallowing, the orally acceptable carrier is harmless to mammals in an amount as disclosed herein. In general, the orally acceptable carrier is harmless even if it is swallowed inadvertently. Suitable orally acceptable carriers include, for example, one or more of the following: water, thickeners, buffers, humectants, surfactants, abrasives, sweeteners, flavoring agents, pigments, dyes, anticaries, antibacterial agents, whitening agents, desensitizing agents, vitamins, preservatives, enzymes, and mixtures thereof.

[0154] As used herein, "cationic active agent" refers to an agent that is cationic in aqueous solution at neutral pH and provides some benefits such as antimicrobial activity. In oral care formulations, cationic active agents can provide anti-gingivitis, anti-caries and / or anti-erosion activity to teeth, gums or oral cavity. Although in aqueous formulations, the agent will usually be in solution, it can be introduced into formulations prepared in free or salt form. In certain embodiments, for example, in certain oral care formulations, the cationic active agent can be selected from one or more of the following: quaternary ammonium surfactants (such as cetylpyridinium chloride (CPC)), biguanides (such as chlorhexidine digluconate), cationic amino acids (such as arginine), metal cations (such as zinc, calcium or stannous ions) or combinations thereof.

[0155] As used herein, "acidic polymer" refers to a polymer comprising a monomer with an acidic group such as a carboxyl and / or phosphate group, for example, selected from one or more of synthetic anionic linear polycarboxylates and phosphate / acrylate copolymers and mixtures thereof. Acidic polymers should have a relatively low isoelectric point, such as pH 5 or lower. Suitable molecular weight varies with specific polymers, the degree of crosslinking or branching, and the ratio of acidic functional groups, but generally the molecular weight is higher than 5000 g / mol. In various embodiments, acidic polymers may be in a linear or nonlinear (i.e., branched) form or a mixture of linear and branched forms, and the main chain or side chain may contain various hydrophobic parts such as methyl methacrylate monomers, alkane chains, etc., and / or hydrophilic uncharged parts such as PEG or PPG, and parts with acidic functional groups. Examples of acidic polymers include synthetic anionic linear polycarboxylates, phosphate / acrylate copolymers, and combinations thereof, which may be selected from various anionic polymer backbones including vinyl, acrylic acid, and maleic acid. The carboxylate moieties along the polymer backbone may be derived from the monomers themselves, such as in the case of acrylic acid, methacrylic acid or maleic acid, or may result from the hydrolysis of the polymer, such as in the case of polybutyl acrylate. The acidic polymer may be composed of copolymers or homopolymers of acidic functional monomers or mixtures thereof.

[0156] As used herein, a "nonionic polymer" is a water-soluble polymer that does not form ionic species at a relevant pH, e.g., between pH 3 and 10, e.g., selected in certain embodiments from one or more poly(oxyalkylene) polymers, e.g., selected from polyethylene glycol (PEG), polypropylene glycol (PPG), poloxamers (block copolymers of PEG and PPG), random copolymers of PEG and PPG, and mixtures thereof. In some embodiments, the nonionic polymer has a molecular weight of at least 3000D, e.g., 6 kDa to 250 kDa. The molecular weight may vary depending on the specific type of polymer, the degree of branching (if any), and the concentration used. Experiments using, e.g., PEGs with molecular weights between 6 kDa and 35 kDa showed that at lower concentrations, e.g., 3% concentration in a specific combination with other ingredients, a higher molecular weight, e.g., 35 kDa material, was required to form a two-phase system, but in formulations with higher PEG content, a PEG with a lower molecular weight, e.g., 6 kDa, could support a two-phase system. In a particular embodiment, the nonionic polymer comprises a mixture of (i) polyethylene glycol (MW 5 kDa-35 kDa) and (ii) a poloxamer (i.e., an ethylene oxide / propylene oxide block copolymer) such as poloxamer 407, which is a triblock copolymer consisting of a polypropylene glycol central hydrophobic block flanked by two polyethylene glycol hydrophilic blocks, wherein the two PEG blocks have an approximate length of about 101 repeat units and the propylene glycol block has an approximate length of about 56 repeat units, which is commercially available, for example, as Pluronic F127 (BASF).

[0157] As used herein, "polyamine compound" refers to a molecule having at least two primary or secondary amine groups, e.g., having an isoelectric point above pH 8.5, e.g., pH 9-10. Examples of polyamines include ethylenediamine, lysine or histidine, and polymers such as Lupasol P, which is polyethyleneimine. The polyamine must be safe for its intended use. When the composition is an oral care composition, the polyamine must be acceptable to the oral cavity. The polyamine can be provided in free or acid addition salt form. In certain embodiments, the polyamine compound is lysine.

[0158] As used herein, "biphasic" refers to a stable liquid composition containing at least two distinct homogeneous phases having different densities such that the phases are separate when standing. These phases can be easily mixed by shaking, but then re-separate in a short time, such as less than half an hour. In certain embodiments, the term excludes gels, emulsions, microemulsions, and homogeneous solutions. In certain embodiments, these formulations differ from conventional biphasic formulations in that both phases are aqueous, rather than one phase being hydrophobic and the other being hydrophilic.

[0159] As used herein, "isoelectric point" is the pH in an aqueous solution at which a molecule has no net charge. To form a two-phase system, three components are required, two of which are charged - a polyamine compound, such as lysine, and an acidic polymer, such as DV8801 or Gantrez. For example, due to its two amines and one carboxylic acid, the isoelectric point of lysine occurs at pH 9.7 (at which only one amine is positive and the acid is negative). At every other pH, lysine contains a certain degree of charge, either overall positive (<pH 9.7, both amines are protonated) or negative (>pH 9.7, both amines are deprotonated - neutral - and the acid group has a negative charge). Acidic polymers, such as DV8801 or Gantrez S-97, have an isoelectric point only at low pH <5, at which the carboxylic esters are all protonated, resulting in 0 net charge. The two-phase system exists between the isoelectric points of the essential materials.

[0160] As used herein, "phosphate / acrylate copolymer" refers to a polymer composed of acrylate monomers and monomers with phosphate esters, such as a copolymerization product of a mixture of acrylic acid, methacrylic acid, and 2-hydroxyethyl methacrylate phosphate of formula 1:

[0161]

[0162] where n is 0, 1, or 2. In some embodiments, the phosphate / acrylate copolymer is a copolymerization product of a mixture of acrylic acid, methacrylic acid, and 2-hydroxyethyl methacrylate phosphate of formula 1, comprising 80 - 90%, such as about 85%, mole percent of acrylic acid; 5 - 15%, such as about 11%, mole percent of methacrylic acid, and 2 - 6%, such as about 4%, mole percent of 2-hydroxyethyl methacrylate phosphate of formula 1. In some embodiments, the phosphate / acrylate copolymer has an average molecular weight of 10 to 40 kDa, such as 20 to 30 kDa. The phosphate / acrylate copolymer as described includes commercially available polymers, such as DV8801 (Rhodia), sometimes referred to as DV herein. As disclosed herein, the phosphate side groups of the phosphate / acrylate copolymer can act as an anchor to deposit the copolymer onto the tooth surface, thereby forming a physical layer on the tooth surface that can inhibit coloring and / or biofilm formation. For example, in a specific embodiment (the embodiment employed in the examples below), the phosphate / acrylate copolymer is a random copolymer with a weight average molecular weight of about 20,000 to 30,000 grams per mole, and the random copolymer is a copolymerization product of a mixture of 2-hydroxyethyl methacrylate phosphate, acrylic acid, and methacrylic acid in the relative amounts given in Table 1 below.

[0163] Table 1.

[0164]

[0165] As used herein, "synthetic anionic linear polycarboxylates" refers to polymers synthesized by using olefinic or ethylenically unsaturated carboxylic acids, wherein the carboxylic acid contains activated carbon-carbon olefinic double bonds and at least one carboxyl group. The acid contains an olefinic double bond that is easily functional in polymerization because it is present in the monomer molecule in the α-β position relative to the carboxyl group or as part of a terminal methylene group. Examples of such acids include acrylic acid, methacrylic acid, ethacrylic acid, α-chloroacrylic acid, crotonic acid, β-acryloxypropionic acid, sorbic acid, α-chlorosorbic acid, cinnamic acid, β-styryl acrylic acid, mucofuric acid, itaconic acid, citraconic acid, mesaconic acid, glutaconic acid, aconitic acid, α-phenylacrylic acid, 2-benzylacrylic acid, 2-cyclohexylacrylic acid, angelic acid, umbelliferous acid, fumaric acid, maleic acid, and anhydride. Other olefinic monomers that can be copolymerized with such carboxyl monomers include vinyl acetate, vinyl chloride, dimethyl maleate, and the like. Synthetic anionic linear polycarboxylates are primarily hydrocarbons with optional halogen and O-containing substituents and bonds (such as present in ester, ether and OH groups). The copolymers preferably contain sufficient carboxyl salt groups for water solubility. The terms "synthetic" and "linear" do not include known thickeners or gelling agents including carboxymethylcellulose and other cellulose derivatives and natural gums, nor do they include carbomers which have reduced solubility due to crosslinking.

[0166] In some embodiments, "synthetic anionic linear polycarboxylates" refer to 1:4 to 4:1 copolymers of maleic anhydride or acid with another polymerizable ethylenically unsaturated monomer, such as methyl vinyl ether (methoxyethylene), having a molecular weight (MW) of about 30,000 to about 2,500,000; for example, 1:4 to 4:1, such as about 1:1 copolymers of methyl vinyl ether / maleic anhydride, wherein the anhydride is hydrolyzed after copolymerization to provide the corresponding acid, having a molecular weight (MW) of about 30,000 to about 1,000,000, such as about 300,000 to about 800,000, such as those sold under the trade name Available, for example, as pharmaceutical grade from Ashland Specialty Chemicals, Bound Brook, NJ 08805 S-97 (MW approximately 700,000).

[0167] As used herein, "tartar control agent" refers to a compound or mixture of compounds that will inhibit the formation of tartar (calcium phosphate compounds) on organic substrates and / or the deposition of dental plaque on teeth to form tartar (calculus).

[0168] As used herein, "chemical staining" refers to discoloration of a surface caused by adsorption or absorption of a colorant on or into a surface (e.g., a tooth surface) or by a chemical reaction of a surface (e.g., enamel) material with a colorant or colorless agent contacting the surface. "Chemical staining" herein refers to the formation and / or development of chemical staining.

[0169] As used herein, "tooth surface" refers to the surface of a natural tooth or the hard surface of artificial dentition, including crowns, caps, fillings, bridges, dental implants, etc. In some embodiments, the tooth surface is a natural tooth.

[0170] Oral care composition: In some embodiments, the composition is an oral care composition, such as a mouthwash, for example, according to Composition 1 et seq. Any of Composition 1 et seq. is suitable for oral care use as long as the ingredients are orally acceptable. In some embodiments, the mouthwash of Composition 1 comprises an effective amount of an orally acceptable cationic active agent, which is an antimicrobial, anti-gingivitis, anti-erosion and / or anticaries agent, such as a cationic active agent selected from one or more of the following: a quaternary ammonium surfactant (such as cetylpyridinium chloride (CPC)), a biguanide (such as chlorhexidine digluconate), a cationic amino acid (such as arginine), a metal cation (such as zinc, calcium or stannous ion), or a combination thereof. The orally acceptable cationic active agent may be present in an effective amount, such as an antimicrobial, anti-gingivitis, anti-erosion and / or anticaries amount. The exact amount will depend on the specific active agent and the condition to be treated or prevented, but in various embodiments, the antimicrobially effective content of CPC in the mouthwash comprises an amount of 0.05 to 0.1%, such as about 0.075%; the antimicrobially effective content of chlorhexidine digluconate in the mouthwash comprises an amount of 0.1-0.2%, such as about 0.12%; the anti-corrosion or antimicrobial content of a metal cation such as zinc (e.g., zinc citrate or other soluble salts) or stannous (e.g., stannous fluoride and / or stannous chloride) will be approximately 100-1500 ppm.

[0171] The oral care compositions used in the present disclosure contain significant amounts of water. Water used in the preparation of commercial oral compositions should be deionized and free of organic impurities. The amount of water in the composition includes the free water added plus the amount of water introduced with other materials.

[0172] Mouthwashes typically contain significant amounts of ethanol, which is often required to dissolve essential oils and prevent bacterial contamination. High levels of ethanol may be undesirable because, in addition to the potential for abuse through ingestion, ethanol may also exacerbate conditions such as dry mouth. Thus, in some embodiments, the oral care compositions of the present invention are substantially free of ethanol, e.g., contain less than 1% ethanol.

[0173] Wetting agent can improve the viscosity, mouthfeel and the sweetness of product, and can also help preserve product and make it avoid degradation or microbial contamination.Suitable wetting agent comprises edible polyhydroxy alcohol, for example the mixture of glycerine, sorbitol, xylitol, propylene glycol and other polyols and these wetting agents.Sorbitol can provide the hydrogenated starch hydrolysate of syrup form in some cases, it mainly comprises sorbitol (if starch is fully hydrolyzed into glucose and then hydrogenated product), but due to the existence of incomplete hydrolysis and / or non-glucose sugar, therefore also may comprise other sugar alcohols such as mannitol, maltitol and long-chain hydrogenated sugar, and these other sugar alcohols also can be used as wetting agent in this case.In certain embodiments, wetting agent exists with the content of 5 % by weight to 30 % by weight, for example 10 % by weight to 20 % by weight.

[0174] Flavoring agents used in the present invention may include: extracts or oils from flavor plants such as mint, spearmint, cinnamon, wintergreen, and combinations thereof; cooling agents such as menthol, methyl salicylate, and commercially available products such as Symrise and sweeteners, which may include polyols (which may also serve as humectants), saccharin, acesulfame K, aspartame, neotame, stevia, and sucralose.

[0175] Also provided is a method of treating and / or inhibiting chemical staining, plaque and / or tartar on a tooth surface (Method A), comprising shaking a composition according to any one of Composition 1 et seq. to disperse the phases and contact the tooth surface therewith.

[0176] This article also provides the following method A:

[0177] A.1 Method A, wherein the composition is Composition 1 et seq., for example, wherein the ingredients are orally acceptable, for example, wherein the composition is a mouthwash.

[0178] A.2 Method A or A.1, wherein the method is used to treat chemical staining, plaque and / or tartar on tooth surfaces.

[0179] A.3 Method A.2, wherein the method is used to treat chemical staining on tooth surfaces.

[0180] A.4 Method A.2, wherein the method is used to treat dental plaque on a tooth surface.

[0181] A.5 Method A.2, wherein the method is used to treat dental plaque on a tooth surface.

[0182] A.6 Method A or A.1, wherein the method is used to inhibit chemical staining, plaque and / or tartar on tooth surfaces.

[0183] A.7 Method A.6, wherein the method is used to inhibit chemical staining on a tooth surface.

[0184] A.8 Method A.6, wherein the method is used to inhibit dental plaque on tooth surfaces.

[0185] A.9 Method A.6, wherein the method is used to inhibit dental plaque on tooth surfaces.

[0186] A.10 Method A or A.1-A.9, wherein the dental surface is a human tooth.

[0187] A.11 Method A or A.1-A.10, wherein the composition is contacted with the tooth surface by brushing.

[0188] Also provided is a method for treating and / or inhibiting gum disease (Method B), comprising shaking the composition according to any one of Composition 1 et seq. to disperse the phases and contact the oral cavity therewith.

[0189] This article also provides the following method B:

[0190] B.1 Method B, wherein the composition is Composition 1 et seq., for example, wherein the ingredients are orally acceptable, for example, wherein the composition is a mouthwash.

[0191] B.2 Method B or B.1, wherein the method is used to treat gum disease.

[0192] B.3 Method B, B.1 or B.2, wherein the gum disease is gingivitis.

[0193] B.4 Method B, B.1 or B, wherein the gum disease is periodontitis.

[0194] B.5 Method B or B.1, wherein the method is used to inhibit gum disease.

[0195] B.6 Method B, B.1 or B.5, wherein the gum disease is gingivitis.

[0196] B.7 Method B, B.1 or B.5, wherein the gum disease is periodontitis.

[0197] B.8 Method B or B.1-B.7, wherein the oral cavity is a human oral cavity.

[0198] B.9 Method B or B.1-B.8, wherein the composition is contacted with the oral cavity by brushing the teeth.

[0199] Also provided is a method for treating and / or inhibiting bad breath (Method C), comprising shaking the composition according to any one of Composition 1 et seq. to disperse the phases and bring the oral cavity into contact therewith.

[0200] This article also provides the following method C:

[0201] C.1 Method C, wherein the composition is Composition 1 et seq., for example, wherein the ingredients are orally acceptable, for example, wherein the composition is a mouthwash.

[0202] C.2 Method C or C.1, wherein the oral cavity is a human oral cavity.

[0203] C.3 Method C, C.1 or C.2, wherein the composition is contacted with the oral cavity by brushing the teeth.

[0204] Also provided is a method for inhibiting biofilm formation on a tooth surface (Method D), comprising shaking the composition according to any one of Composition 1 et seq. to disperse the phases and contact the tooth surface therewith.

[0205] This article also provides the following method D:

[0206] D.1 Method D, wherein the composition is Composition 1 et seq., for example, wherein the ingredients are orally acceptable, for example, wherein the composition is a mouthwash.

[0207] D.2 Method D or D.1, wherein the dental surface is a human tooth.

[0208] D.3 Method D, D.1 or D.2, wherein the composition is contacted with the tooth surface by brushing.

[0209] Also provided is a method for treating and / or inhibiting bacteria from sticking together and growing into larger colonies in the oral cavity (Method E), which comprises shaking the composition according to any one of Composition 1 et seq. to disperse the phases and contact the tooth surface therewith and the oral cavity therewith.

[0210] This article also provides the following method E:

[0211] E.1 Method E, wherein the composition is Composition 1 et seq., for example, wherein the ingredients are orally acceptable, for example, wherein the composition is a mouthwash.

[0212] E.2 Method E or E.1, wherein the oral cavity is a human oral cavity.

[0213] E.3 Method E, E.1 or E.2, wherein the composition is contacted with the oral cavity by brushing the teeth.

[0214] Also provided is Composition 1 et seq. for use in any of Methods AE.

[0215] As used herein, "inhibit" refers to a reduction in staining that would otherwise develop or progress after the treatment period. Such inhibition may vary from a small but observable or measurable reduction to a complete inhibition of subsequent staining compared to an untreated or placebo-treated tooth surface.

[0216] In the case where there is substantially no chemical staining on the tooth surface, after treatment according to the method, method A (e.g., A.1-A.11) will effectively inhibit the formation and development of new chemical staining that may occur, for example, due to oral use of tobacco products (including smoking) or due to drinking tea, coffee, red wine or cola. In the case where there is already a certain degree of chemical staining on the tooth surface, method A (e.g., A.1-A.11) will effectively inhibit the further development of existing staining. In some embodiments, method A (e.g., A.1-A.11) can partially or completely remove existing chemical staining and inhibit subsequent staining.

[0217] Examples

[0218] Example 1 - Development of a biphasic solution

[0219] Phase Separation - General Rhodia DV8801 (i.e. Mirapol 8801) (DV), lysine (Lys) and polyethylene glycol (PEG) with various molecular weights were mixed. MW ) were mixed together to produce a biphasic solution with a PEG concentrated layer at the top and a DV-Lys concentrated layer at the bottom. 6000 , 5% Lys and 4% DV. The solution had a pH of 6. The two phases were clear and could be easily seen and distinguished by adding a blue dye as the dye made one phase darker than the other. 在D The 1H NMR data of the top and bottom layers in 2O solvent showed that PEG was concentrated in the top layer, while lysine and DV were concentrated in the bottom layer.

[0220] Table 1 shows a series of solutions in which the percentages of DV, PEG and lysine were varied to identify the parameters required to form a two-phase solution. Two drops of a blue water-soluble dye were added to each solution for comparison. No separation was observed at low levels of all three components, represented by solutions 1-3. Solutions 4 and 10 represent the minimum levels of DV, PEG and lysine required to form a stable phase separation state.

[0221] The extent to which phase separation occurs can be adjusted by varying the relative amounts of the polymers, which in turn can effectively control the aesthetics of the solution.

[0222] Table 1: Composition of biphasic solutions in water, whether phase separation (PS) was observed (Y = yes, N = no) and the mass percentage of the top layer.

[0223] Solution DV% <![CDATA[PEG 6000 %]]> Lys% PS Quality Top % 1 4 2 0 N - 2 4 2 5 N - 3 4 6 0 N - 4 4 6 5 Y 51.6 5 12 2 0 Y 7.4 6 12 2 5 Y 10.2 7 12 6 0 Y 25.9 8 12 6 5 Y 24.5 9 8 4 2.5 Y 25.6 10 2.5 6 5 Y -

[0224] Phase separation - color control : In most cases, the blue dye was mainly located in the upper part of the two-phase solution. In the case of adding 0.075% CPC, the blue dye shifted to the bottom layer, probably due to the interaction with CPC and dye molecules. Although 0.075% CPC is common for mouthwash formulations, this effect was achieved at 0.0065%. 0.075% CPC showed clear phase separation. In some cases, precipitation occurred after adding CPC, however, after a slight warming to >40°C in a water bath, the solid dissolved and no reprecipitation was observed.

[0225] Phase separation control Solution 4 was compared to the same composition with the same mass of NaCl replacing Lys to determine the extent to which salt concentration plays a role in the PS state. Phase separation was achieved by NaCl, however, the extent was reduced by about 20% (although the same mass of NaCl and Lys was equivalent to a higher molar amount of NaCl), suggesting that Lys plays a role in defining the internal solution dynamics through hydrogen bonding and other ionic means.

[0226] Self-diagnosis - time adjustable separation Due to the dynamic nature of phase separation, the volume difference between the top and bottom layers can be slightly adjusted, and the time for adequate separation can be adjusted. 6000 / 5Lys / 4DV solution and 2PEG 300K / 5Lys / 4DV and continued for several time points thereafter. Solutions containing higher MW PEG showed much faster separation times compared to lower MW.

[0227] change.Variations of this formulation include PEG with a MW of 600-1,000,000. The amino acids may be selected from lysine, arginine, histidine, glutamic acid, aspartic acid, with supplements from carnitine and other supplements. The hydrophilic polymer may be a polymer or copolymer containing monomers of acrylic acid, methacrylic acid, ethylene glycol methacrylate phosphate, 2-hydroxyethyl methacrylate or selected from commercial sources such as Mirapol 8801 (Rhodia DV8801), Gantrez (Ashland), Tamol 731A (Dow), etc., and includes polymers that are considered dispersants. The formulation may also include anionic surfactants such as sodium lauryl sulfate, Zetesol ZN, sodium cocoyl alcohol polyether sulfate, etc. It may include non-ionic surfactants commonly used in oral ingredients, such as poloxamers. It may include zinc ions derived from zinc salts and anions chloride ions, nitrates, sulfates, acetates, citrates, etc. The formulation may also include actives common to mouthwashes and toothpastes, such as cetylpyridinium chloride.

[0228] Example 2 - CPC Formulation

[0229] In this system, two layers will be formed. When cationic active compounds such as CPC and Zn are added 2+ When the top and bottom layers are 1 H NMR revealed that the spectrum of the top layer did not show any evidence of CPC. The bottom layer contained signals characteristic of CPC, indicating that CPC was localized in a single layer of the biphasic system.

[0230] Results and Zn 2+ Analysis of the top and bottom layers containing a total of 1% ZnCl2 (4800 ppm) by atomic absorption showed the presence of a concentration gradient. 2+ The concentration of Zn was measured in the top layer to be 1400 ppm 2+ , the bottom is 8800 ppm, that is, 6.3 times higher than the top concentration.

[0231] This effect is useful because when the formulation is shaken to form a dispersion of underlying droplets, the droplets that contact the teeth contain a high concentration of active, but the overall concentration of active in the formulation is relatively low.

[0232] CPC Efficacy.Various compositions containing 0.075% CPC were compared to demonstrate the need for Lys and Glu in the system. For example, CPC is generally incompatible with anionic polymers such as DV8801 because precipitation of the two components will occur. The addition of Lys will provide the required stability and competition between the acid functionality of the polymer, the acid and amine of Lys, and CPC - each acting on free CPC and making it more available for interaction with bacteria. The addition of Glu also improves CPC through an additional competitive pathway via the carboxylate on Glu. In the absence of lysine, the DV / PEG / CPC complex approaches the efficacy of the material without CPC or the vehicle control.

[0233] Table 2: Antimicrobial efficacy

[0234]

[0235]

[0236] CHX = cetylpyridinium chloride; DV = DV8801 (phosphate / acrylate copolymer); S-97 = Gantrez S-97 (copolymer of methyl vinyl ether and maleic anhydride); Lys = lysine hydrochloride; SLS = sodium lauryl sulfate (anionic surfactant); PEG 10K = polyethylene glycol with a molecular weight of approximately 10 kD (non-ionic surfactant).

[0237] Example 3 - CPC Absorption

[0238] The charge of active CPC and chlorhexidine is cationic. Combinations of these with anionic polymers such as phosphate-containing DV8801 (Mirapol 8801) or Gantrez usually render them inactive by complexation or precipitation. Biofilm removal is increased when the amino acid Lys (and Glu) is added, which acts on the free CPC from the anionic polymer by competing charge interactions, thereby increasing its efficacy.

[0239] CPC absorption studies were performed on saliva-coated hydroxyapatite (HAP) disks. 24 HAP disks were incubated overnight at 37°C in 1 mL (each) of saliva supernatant (obtained by centrifuging whole saliva at 8000 rpm for 15 minutes). Saliva was aspirated. Each disk was treated with 1 mL of mouthwash and vortexed for 5 seconds. The treated disks were incubated at 37°C for 30 minutes. The mouthwash was removed from the disks, and the disks were rinsed with 5 mL of deionized water and vortexed for 5 seconds. The rinse water was removed and each disk was transferred to a clean 15 mL tube. The disks were each treated with 2 mL of ethanol (200 proof), vortexed for 15 seconds, and allowed to stand at room temperature for 30 minutes to ensure that the active was fully extracted from the disks. The ethanol was then filtered into an HPLC vial using a 0.45 micron syringe-free filter for analysis.

[0240] Table 3: CPC absorption

[0241] Composition No. Composition (weight %) CPC absorption (ppm) 1 6PEG / 0.075CPC 58.7 2 6PEG / 2.5DV / 0.075CPC 15.0 3 6PEG / 5Lys / 2.5DV / 0.075CPC 55.7 4 3PEG / 4Lys / 1Glu / 2.5DV / 0.075CPC 51.7 5 3PEG / 5Lys / 2.5DV / 0.075CPC 42.3 6 6PEG / 5Glu / 2.5DV / 0.075CPC 40.7

[0242] Each sample solution contained 0.075% CPC in combination with the materials present in these biphasic solutions. Composition 1 contained CPC in the presence of PEG 6k and represents a control since no deactivated material was present in the solution. Once DV8801 was added to the mixture (Composition 2), CPC absorption was significantly reduced (this sample contained a precipitate). Addition of Lys (Composition 3) allowed CPC absorption to return to control levels, indicating that CPC was not so strongly bound to DV as to inactivate it. Replacing 1% Lys with 1% Glu resulted in approximately equivalent CPC efficacy.

[0243] In composition 5, PEG 6k was reduced to 3%, resulting in a single-phase solution. It can be seen that CPC absorption was slightly negatively affected, suggesting that the biphasic solution structure facilitates CPC adsorption to the surface. Finally, Lys was completely replaced by Glu in composition 6. Although this sample allowed CPC delivery, the efficacy was significantly lower than the control and / or biphasic standard solution in composition 3.

[0244] Example 4: Formulation Optimization

[0245] Below are several tables detailing the quality requirements for forming a two-phase solution, as well as the changes in the listed materials to demonstrate the MW and usage content conditions for phase separation. For example, in the PEG content, the solution composition is 1% DV / 1% S-97 / 4% Lys / 3% PEG, where the MW of PEG varies from 600→35.000 g / mol; the PEG species used at 3% is indicated and a two-phase system is formed. Note: PEG 10K and PEG 6K do form a two-phase system, but only when used at higher usage levels. Similarly, arginine or histidine will support a two-phase system, but only at higher concentrations. The units of material amounts are weight %. Results are provided as the number of phases in the solution.

[0246] PEG content

[0247]

[0248] Amino Acid Type

[0249]

[0250] Amino Acid Content

[0251]

[0252] *Biphasic solution was prepared using 1DV / 1S-97 / 4PEG 10K / 5His at pH 5.95.

[0253] Acidic polymer MW

[0254]

[0255] Example 5 - Oral Care Formulations with CPC

[0256] An aqueous dual phase mouthwash formulation was prepared with the following ingredients:

[0257] Material content(%) Active matter (%) Usage content (%) water Moderate N / A 81.19 Lysine hydrochloride 4 100 4 PEG 8k 4 100 4 DV 1 41 2.439 Gantrez S-97 1 16.5 6.061 CPC 0.075 100 0.075 Saccharin Sodium 0.0185 100 0.019 Potassium Sorbate 0.0519 100 0.052 Poloxamer 407 1 100 1 Sodium hydroxide 0 50 0 Propylene glycol 1 100 1 Optacool 0.026 100 0.026 Menthol 0.0185 100 0.019 peppermint 0.1185 100 0.119 Blue #1 0.0006 100 0.001 total 100

[0258] The present invention also relates to the following embodiments (which correspond to the claims of the original application):

[0259] 1. A composition comprising an aqueous solution of:

[0260] a) Acidic polymers;

[0261] b) nonionic polymers;

[0262] c) optionally an effective amount of a cationic active agent;

[0263] d) a stabilizing amount of a polyamine compound; and

[0264] e) water;

[0265] The solution comprises two different aqueous phases having different compositions and densities.

[0266] 2. The composition according to embodiment 1, wherein the acidic polymer is selected from one or more of synthetic anionic linear polycarboxylates, phosphate / acrylate copolymers, and combinations thereof.

[0267] 3. The composition according to embodiment 2, wherein the acidic polymer is selected from the following combinations:

[0268] a) a 1:4 to 4:1 copolymer of maleic anhydride or acid with another polymerizable ethylenically unsaturated monomer, such as a copolymer of methyl vinyl ether / maleic anhydride, wherein some or all of the anhydride moieties are hydrolyzed to provide free carboxyl groups, and

[0269] b) a copolymerization product of a mixture of acrylic acid, methacrylic acid and 2-hydroxyethyl methacrylate phosphate of formula 1:

[0270]

[0271] Where n is 0, 1, or 2.

[0272] 4. The composition according to any preceding embodiment, wherein the nonionic polymer is selected from polyethylene glycol, polypropylene glycol, poloxamer, and random polyethylene glycol / polypropylene glycol copolymers and mixtures thereof.

[0273] 5. The composition according to any preceding embodiment, comprising a cationic active agent selected from one or more of quaternary ammonium surfactants, biguanides, cationic amino acids, metal cations, and combinations thereof.

[0274] 6. A composition according to any preceding embodiment comprising a cationic active agent provided by an orally acceptable salt selected from zinc salts, stannous salts, chlorhexidine digluconate and cetylpyridinium chloride.

[0275] 7. A composition according to any preceding embodiment, wherein the polyamine is lysine, in free or salt form.

[0276] 8. A composition according to any preceding embodiment, wherein the composition comprises 70% to 95% water.

[0277] 9. A composition according to any preceding embodiment, wherein the composition comprises an anionic surfactant.

[0278] 10. A composition according to any preceding embodiment, having a pH of 5.5 to 8.0.

[0279] 11. A composition according to any preceding embodiment comprising less than 5% of hydrophobic components.

[0280] 12. A composition according to any preceding embodiment, which is substantially free of oil, except for the flavoring agent.

[0281] 13. The composition according to any one of embodiments 1 to 12, wherein the composition further comprises an oil phase.

[0282] 14. A composition according to any preceding embodiment, wherein the composition is an oral care composition, wherein the ingredients are orally acceptable, and wherein the composition comprises one or more of the following: a thickener, a buffer, a humectant, a surfactant, an abrasive, a sweetener, a flavoring agent, a pigment, a dye, an anticaries agent, an antibacterial agent, a whitening agent, a desensitizing agent, a preservative, or a mixture thereof.

[0283] 15. A composition according to any preceding embodiment, wherein the composition is a mouthwash.

[0284] 16. The composition according to embodiment 15, wherein:

[0285] a) the acidic polymer comprises a combination of a phosphate ester / acrylate copolymer and a methyl vinyl ether / maleic anhydride copolymer, the total amount being 1% to 5%, for example about 2%;

[0286] b) the nonionic polymer comprises a combination of (i) polyethylene glycol having an average molecular weight of 5 kDa to 35 kDa, such as PEG8k or PEG 35k, and (ii) poloxamer 407, in a total amount of 3 to 10%, such as 2-5% polyethylene glycol and 0.5-2% poloxamer;

[0287] c) the cationic active agent is present in an effective amount, in free or orally acceptable salt form, and comprises cetylpyridinium chloride in an amount of 0.05 to 0.1%, such as about 0.075%;

[0288] d) the polyamine in free or salt form is lysine; and

[0289] e) the water is present in an amount of 70-95%, such as about 85-90%;

[0290] wherein the composition further comprises a humectant, such as 1%-2.5%, such as about 1% propylene glycol; a flavoring agent; a sweetener; a preservative (such as 0.04%-0.06% potassium sorbate); and a dye (such as blue dye #1);

[0291] wherein all ingredients are orally acceptable, e.g., safe and palatable at concentrations relevant for use in mouthwash; and

[0292] All amounts herein are based on weight of the total composition.

[0293] 17. A composition according to any preceding embodiment, wherein

[0294] a) the acidic polymer is selected from phosphate / acrylate copolymers, methyl vinyl ether / maleic anhydride copolymers and mixtures thereof, with a total amount of 1 to 12%;

[0295] b) the nonionic polymer is selected from polyethylene glycol with a molecular weight of 5 kD to 35 kD and poloxamer 407 in an amount of 0 to 2% and mixtures thereof, with a total amount of 3 to 10%;

[0296] c) the effective amount of an orally acceptable cationic active agent in free or orally acceptable salt form is present in an amount of 0.05 to 0.1% and comprises cetylpyridinium chloride;

[0297] d) the polyamine compound comprises lysine in the form of free or orally acceptable salts in a total amount of 1 to 10%; and

[0298] e) the water is present in an amount of 35-95%;

[0299] wherein the composition optionally further comprises an anionic surfactant and / or glutamic acid; and

[0300] All amounts herein are based on weight of the total composition.

[0301] 18. A composition according to any one of compositions 1 to 1.86 above.

[0302] 19. A method according to any one of methods A to E above.

Claims

1. A composition comprising an aqueous composition of: a) an acidic polymer present in a total amount of 1% to 5%, wherein the acidic polymer comprises a combination of (i) a copolymer of maleic anhydride and methyl vinyl ether and (ii) a copolymerization product of a mixture of acrylic acid, methacrylic acid and a compound of Formula 1: wherein the compound is a mixture of phosphate ions / phosphoric acid and 2-hydroxyethyl methacrylate phosphate of formula 1 wherein n is 1 and 2; b) a nonionic polymer comprising a combination of (i) polyethylene glycol having an average molecular weight of 5 kDa to 35 kDa and (ii) poloxamer 407, the total amount of which is 3 to 10%, wherein the amount of polyethylene glycol having an average molecular weight of 5 kDa to 35 kDa is 5% to 8%; c) an effective amount of a cationic active agent, wherein the cationic active agent is cetylpyridinium chloride, in an amount of 0.05 to 0.1%; d) a polyamine compound comprising lysine in free form in an amount of 1% to 5% by weight or in salt form of lysine in an amount of 1% to 5% by weight; and e) water, said water being present in an amount of 70-95%; wherein the composition is a mouthwash and comprises two different aqueous phases having different compositions and densities; wherein the composition further comprises a humectant, a flavoring agent, a sweetener, a preservative and a dye; wherein all ingredients are orally acceptable, safe and palatable at relevant concentrations for use in mouthwashes; and All amounts herein are by weight of the total composition.

2. A composition according to claim 1 wherein in the copolymer of methyl vinyl ether / maleic anhydride some or all of the anhydride moieties are hydrolysed to provide free carboxyl groups.

3. A composition according to any preceding claim, wherein the composition comprises an anionic surfactant.

4. The composition according to claim 1, having a pH of 5.5 to 8.

0.

5. The composition of claim 1 comprising less than 5% of a hydrophobic component.

6. The composition of claim 1 which is oil-free except for flavoring agents.

7. The composition of claim 1, wherein the composition comprises one or more of the following: a thickener, a buffer, a surfactant, an abrasive, a pigment, an anticaries agent, an antibacterial agent, a whitening agent, a desensitizing agent, or a mixture thereof.

8. The composition according to claim 1 or 2, wherein a) the acidic polymer comprises a combination of (i) a copolymer of maleic anhydride and methyl vinyl ether and (ii) a copolymerization product of a mixture of acrylic acid, methacrylic acid and a compound of Formula 1, the total amount being 2%: wherein the compound is a mixture of phosphate ions / phosphoric acid and 2-hydroxyethyl methacrylate phosphate of formula 1 wherein n is 1 and 2; b) the nonionic polymer comprises 5% to 8% polyethylene glycol and 0.5% to 2% poloxamer; c) the cationic active agent comprises cetylpyridinium chloride in an amount of 0.075%; d) the polyamine is lysine in free or salt form; and e) the water is present in an amount of 85-90%; The moisturizing agent comprises 1% to 2.5% of propylene glycol.

9. The composition according to claim 1, wherein the composition optionally further comprises an anionic surfactant and / or glutamic acid.